Durvalumab in combination for neoadjuvant and adjuvant treatment of resectable gastric and gastro-oesophageal junction cancer [ID6374]

  • In development
  • GID-TA11440
  • Expected publication date: TBC

Documents

Documents created during the development process.

Invitation to participate

Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators

Topic selection